CDK4/6 inhibitors have proven so effective in metastatic settings that abemaciclib has been newly approved for HR-positive/HER2-negative early-breast cancer patients at high-risk of recurrence [180,181]. This evidence concerns the gene ERBB2 and breast carcinoma.